Cargando…

PB2137: INFLUENCE OF PREVIOUS RADIOTHERAPY ON THE EFFECT OF CART CELL THERAPY IN AGGRESSIVE B-CELL LYMPHOMA

Detalles Bibliográficos
Autor principal:	Shaomei, F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431715/ http://dx.doi.org/10.1097/01.HS9.0000851380.92776.b7

Ejemplares similares

PB2137: SOCIO-DEMOGRAPHIC FEATURES AND TREATMENT PATTERNS OF MULTIPLE MYELOMA PATIENTS IN SPAIN: AN INTERIM ANALYSIS OF DORIANT STUDY
por: Montes-Gaisán, Carmen, et al.
Publicado: (2023)

PB2161: CHARACTERISTICS OF AGGRESSIVE B-CELL LYMPHOMAS WITH MYC REARRANGEMENT
por: Ortuzar Pasalodos, A., et al.
Publicado: (2022)

PB2101: A PROSPECTIVE INVESTIGATION INTO THE TIMING AND STATUS OF BCMA-CART IN SECONDARY PLASMA CELL LEUKEMIA
por: Guo, Yuelu, et al.
Publicado: (2023)

PB2101: TREATMENT OF AGGRESSIVE B-CELL LYMPHOMA WITH DA-EPOCH-R, A SINGLE CENTRE EXPERIENCE
por: Dimitraki, E.-K., et al.
Publicado: (2022)

PB2168: BRUSATOL INDUCES APOPTOSIS IN AGGRESSIVE LYMPHOMA CELLS IN VITRO AND SYNERGIZES WITH VENETOCLAX
por: Szmyra, M., et al.
Publicado: (2022)

PB2157: TREATMENT WITH DIPHENYLENEIODONIUM CHLORIDE EXHIBITS CELL GROWTH INHIBITORY EFFECTS ON AGGRESSIVE LYMPHOMA CELLS
por: Haingartner, S., et al.
Publicado: (2022)

PB2097: ZANUBRUTINIB PLUS RITUXIMAB FOR THE TREATMENT OF ELDERLY UNFIT PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE-B CELL LYMPHOMA
por: Bai, J.-F., et al.
Publicado: (2022)

PB1738: OBSERVATION OF THERAPEUTIC EFFECT OF BLINATUMOMAB SALVAGE TREATMENT ON B – ALL WITH INVALID OR RECURRENT CART
por: Yuehui, Lin
Publicado: (2023)

PB2333: CAR-T CELL THERAPY IS A EXCELLENT STRATEGY FOR R/R B-NHL
por: Rui, Liu, et al.
Publicado: (2023)

PB2093: DIFFUSE LARGE B CELL LYMPHOMA IN THE ELDERLY
por: Abichou, G., et al.
Publicado: (2022)

PB2289: PRELIMINARY DATA FROM A FIRST-IN HUMAN PHASE II STUDY OF SEQUENTIAL USE OF SELINEXOR AND CD19 CHIMERIC ANTIGEN RECEPTOR MODIFIED T-CELL THERAPY (CART19) IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
por: Zhang, Ying, et al.
Publicado: (2023)

PB2064: RELAPSED/REFRACTORY HODGKIN LYMPHOMA PATIENTS TREATED WITH RADIOTHERAPY
por: Kallel, F., et al.
Publicado: (2022)

PB2155: B-CELL NON-HODGKIN’S LYMPHOMAS ASSOCIATED WITH AMYLOIDOSIS
por: Navrátilova, M., et al.
Publicado: (2022)

PB2332: CLINICAL CHARACTERISTICS AND OUTCOMES OF HIV-ASSOCIATED AGGRESSIVE B-CELL NHL IN CHINA
por: Wang, Chaoyu, et al.
Publicado: (2023)

PB2123: MANAGEMENT OF PATIENTS WITH CONCOMITANT LIVER CIRRHOSIS AND AGGRESSIVE LYMPHOMA – A LITERATURE REVIEW
por: Jelicic, J., et al.
Publicado: (2022)

PB2326: OUTCOMES OF ANTI-CANCER THERAPY IN PATIENTS WITH PROGRESSIVE REFRACTORY/RELAPSED B-CELL LYMPHOMA DURING SEVERE CORONAVIRUS DISEASE 2019 (COVID-19): A REAL-WORLD STUDY FROM CHINA
por: Su, Guoai, et al.
Publicado: (2023)

PB2162: INCREASED OXIDATIVE STRESS IN DIFFUSE LARGE B-CELL LYMPHOMA
por: Antic, D., et al.
Publicado: (2022)

PB2071: INTRALESIONAL RITUXIMAB IN THE TREATMENT OF PRIMARY CUTANEOUS B-CELL LYMPHOMA
por: Callejas Charavia, M., et al.
Publicado: (2022)

PB2343: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB VERSUS STANDARD OF CARE THERAPY IN RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA (OLYMPIA-4)
por: Hawkes, Eliza A., et al.
Publicado: (2023)

PB2366: TRIAL IN PROGRESS: PHASE 1 TRIAL EVALUATING THE SAFETY AND TOLERABILITY OF ODRONEXTAMAB IN COMBINATION WITH CEMIPLIMAB IN RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA
por: Segura, Cecilia Carmen Carpio, et al.
Publicado: (2023)

PB2094: PRIMARY MEDIASTINAL B-CELL LYMPHOMA: EXPERIENCE OF THE HEMATOLOGY DEPARTMENT OF SFAX
por: Charfi, M., et al.
Publicado: (2022)

PB2164: PROGNOSTIC IMPACT OF ONCOGENE DEK IN DIFFUSE LARGE B-CELL LYMPHOMA
por: Alonso Alonso, R., et al.
Publicado: (2022)

PB2373: A SINGLE-CELL ATLAS OF HIV-ASSOCIATED DIFFUSE LARGE B-CELL LYMPHOMA
por: Zhang, Xiaomei, et al.
Publicado: (2023)

PB2145: REAL-WORLD THERAPY LINES IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) – A POPULATION-BASED ANALYSIS
por: Duell, J., et al.
Publicado: (2022)

PB2320: FIRST LINE THERAPY FOR DIFFUSE LARGE B CELL LYMPHOMA AMONG THE ELDERLY: A TUNISIAN MULTICENTER EXPERIENCE.
por: Zahra, Kmira, et al.
Publicado: (2023)

PB2453: FACTORS INFLUENCING AUTOLOGOUS PERIPHERAL BLOOD STEM CELL MOBILIZATION IN LYMPHOMA AND MULTIPLE MYELOMA
por: Longrong, Ran, et al.
Publicado: (2023)

PB2154: TP53 GENE MUTATION DIVERSITY IN RUSSIAN PATIENTS WITH B-CELL LYMPHOMAS
por: Biderman, B., et al.
Publicado: (2022)

PB2129: COULD LYMPHOPENIA PREDICT OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA?
por: Merchan Muñoz, B., et al.
Publicado: (2022)

PB2327: IS THERE ANY VALUE OF GERIATRIC INDICES IN DIFFUSE LARGE B CELL LYMPHOMA OF THE ELDERLY?
por: Dragčević, Dora, et al.
Publicado: (2023)

PB2313: THE PROGNOSTIC SIGNIFICANCE OF APOPTOSIS-INDUCING FACTOR IN DIFFUSE LARGE B-CELL LYMPHOMA
por: Vaneeva, Elena, et al.
Publicado: (2023)

PB1771: THE SIGNIFICANCE OF MRD DETECTION BY FLOW CYTOMETRY IN TRACING R/R B-ALL PATIENTS RECEIVING CD-19-CART BRIDGING TO ALLO-HSCT
por: chen, M., et al.
Publicado: (2022)

PB2369: PERIPHERAL T CELL LYMPHOMA: EPIDEMIOLOGY AND CLINICAL CHARACTERISTICS
por: Charfi, Maha, et al.
Publicado: (2023)

PB2172: IRON OXIDE NANOPARTICLES INHIBIT DIFFUSE LARGE B LYMPHOMA CELL SURVIVAL AND INVASION
por: Yan-Li, L., et al.
Publicado: (2022)

PB2092: PRIMARY BONE DIFFUSE LARGE B CELL LYMPHOMA: A SINGLE CENTER EXPERIENCE
por: Abichou, G., et al.
Publicado: (2022)

PB2374: DIFFERENCES IN MUTATIONAL SIGNATURE OF DIFFUSE LARGE B-CELL LYMPHOMAS ACCORDING TO THE PRIMARY ORGAN
por: Koh, Hyun Hee, et al.
Publicado: (2023)

PB2354: DIFFUSE LARGE B CELL LYMPHOMA IN 65: DIAGNOSTIC, PROGNOSTIC, PROGRESSIVE AND THERAPEUTIC ASPECTS
por: Mlayah, Zaineb, et al.
Publicado: (2023)

PB2156: ANALYSIS OF POSSIBLE CLONAL ORIGIN OF LARGE B-CELL DIFFUSED LYMPHOMAS ARISING IN PATIENTS WITH PRE-EXISTING HODGKIN’S LYMPHOMA
por: Masciopinto, P., et al.
Publicado: (2022)

PB2115: TRIAL IN PROGRESS: A RANDOMIZED PHASE II STUDY OF MB-CART2019.1 COMPARED TO STANDARD OF CARE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL INELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION
por: Borchmann, P., et al.
Publicado: (2022)

PB2328: TRIAL IN PROGRESS: ATHENA-1 – A PHASE 1 STUDY TO ASSESS SAFETY AND TOLERABILITY OF REGN5837 IN COMBINATION WITH ODRONEXTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA
por: Mutsaers, Pim G. N. J., et al.
Publicado: (2023)

PB2273: EFFICACY OF OBINUTUZUMAB - BASED REGIMENS IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA: A RETROSPECTIVE OBSERVATIONAL SINGLE-CENTER STUDY
por: Ridova, Nevenka, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3okmsnp234am31quas3cefsqog